In conclusion, our study showed the usefulness of assessing COX-2 status both in tumour and stroma compartment in order to identify cervical cancer patients endowed with a very poor chance of response to neoadjuvant therapy and unfavourable prognosis. This evidence concerns the gene PTGS2 and cervical cancer.